Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Published:2012-12 Issue:3 Volume:127 Page:451-455
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Alberts David S.,Blessing John A.,Landrum Lisa M.,Warshal David P.,Martin Lainie P.,Rose Stephen L.,Bonebrake Albert J.,Ramondetta Lois M.

Funder

National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office

Gynecologic Oncology Group Statistical and Data Center

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference20 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2011

2. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study;McGuire;J Clin Oncol,1996

3. Paclitaxel and cisplatin as a first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study;Rose;J Clin Oncol,1999

4. Albumin-bound paclitaxel: a next-generation taxane;Gradishar;Expert Opin Pharmacother,2006

5. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions;Micha;Gynecol Oncol,2006

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer;Journal of Cancer Research and Clinical Oncology;2024-06-25

2. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer;BMC Cancer;2024-05-15

3. Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer;Journal of Cancer Research and Clinical Oncology;2024-05-06

4. The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers;Current Pharmaceutical Design;2024-04

5. Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent;Cureus;2024-03-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3